Rheumatology · Rheumatoid Arthritis Complications
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Felty syndrome is defined by the classic triad of rheumatoid arthritis, splenomegaly, and neutropenia.
Patients typically present with a long-standing history of seropositive rheumatoid arthritis characterized by high titers of rheumatoid factor and anti-CCP antibodies.
The hallmark hematologic finding is neutropenia (absolute neutrophil count < 1,500/µL), which significantly increases the risk of recurrent bacterial infections.
Physical examination frequently reveals splenomegaly and may show extra-articular manifestations such as leg ulcers, pigmented skin lesions, or vasculitis.
The underlying pathophysiology involves immune complex deposition and large granular lymphocyte (LGL) proliferation leading to peripheral destruction of neutrophils.
Diagnosis is confirmed by the presence of the clinical triad in the setting of established rheumatoid arthritis after excluding other causes of hypersplenism.
First-line management focuses on controlling the underlying rheumatoid arthritis with methotrexate, with rituximab reserved for methotrexate-refractory disease, while severe cases may require splenectomy or granulocyte colony-stimulating factor (G-CSF).
Vignette unlocked
A 62-year-old woman with a 15-year history of erosive rheumatoid arthritis presents to the clinic for evaluation of a non-healing ulcer on her left medial malleolus. She reports a recent history of two episodes of pneumonia in the last six months. Physical examination reveals splenomegaly on deep palpation and significant joint deformities in the hands. Laboratory studies demonstrate a hemoglobin of 10.2 g/dL, a platelet count of 145,000/µL, and an absolute neutrophil count of 1,200/µL.
What is the most likely diagnosis?
Felty syndrome
The patient presents with the classic triad of long-standing rheumatoid arthritis, splenomegaly, and neutropenia, which defines Felty syndrome.
Full handout
High yield triage
Etiology / Epidemiology
Occurs in approximately 1-3% of patients with long-standing, severe rheumatoid arthritis (RA). Typically presents in the 5th-7th decade of life.
Clinical Manifestations
Classic triad: rheumatoid arthritis, splenomegaly, and neutropenia. Patients often present with recurrent infections.
Diagnosis
Diagnosis is clinical, supported by absolute neutrophil count (ANC) < 1,500/µL. CBC is the essential screening tool.
Treatment
Treat the underlying RA with methotrexate first-line; rituximab if MTX-refractory. Avoid splenectomy unless severe, refractory neutropenia exists.
Prognosis
High risk for recurrent bacterial infections and leg ulcers. Mortality is often linked to infection or malignancy.
Full handout
Epidemiology & Etiology
Felty syndrome is a rare, severe extra-articular manifestation of long-standing RA, occurring in approximately 1-3% of RA patients. It is strongly associated with the HLA-DR4 genotype. Patients typically have high titers of rheumatoid factor (RF).
Pertinent Anatomy
The primary anatomical involvement is the spleen, which undergoes hyperplasia of the reticuloendothelial system. This leads to splenomegaly, which is palpable in the majority of cases.
Pathophysiology
Chronic immune complex deposition leads to splenic sequestration and destruction of neutrophils. The bone marrow often shows myeloid hyperplasia with maturation arrest. This results in peripheral neutropenia, predisposing the patient to severe infections.
Clinical Manifestations
The classic triad is rheumatoid arthritis, splenomegaly, and neutropenia. Patients frequently exhibit pigmented skin lesions on the lower extremities and leg ulcers. Recurrent bacterial infections, particularly of the skin and respiratory tract, are common due to the low ANC.
Diagnosis
Diagnosis rests on neutropenia (ANC < 1,500/µL) in a patient with established RA once other causes are excluded; splenomegaly is characteristic and usually present but is not strictly required. A CBC with differential is the primary diagnostic test. Bone marrow biopsy may be performed to rule out other causes of cytopenia, showing characteristic myeloid hyperplasia.
Treatment
Management focuses on controlling the underlying rheumatoid arthritis with methotrexate as the first-line agent; rituximab is reserved for methotrexate-refractory or methotrexate-intolerant disease. Splenectomy is reserved for patients with life-threatening, recurrent infections or severe, symptomatic neutropenia. Granulocyte colony-stimulating factor (G-CSF) may be used temporarily but carries a risk of worsening systemic inflammation.
Prognosis
Patients face a high risk of recurrent infections and non-Hodgkin lymphoma. Regular monitoring of the CBC is mandatory to track the severity of neutropenia. Long-term outcomes depend on the successful suppression of the underlying autoimmune process.
Differential Diagnosis
Large granular lymphocyte (LGL) leukemia: current literature regards Felty syndrome and LGL leukemia as an overlapping disease spectrum (about one-third of Felty patients have a clonal LGL population); clonal T-cell expansion on flow cytometry does not cleanly rule Felty syndrome out
Systemic Lupus Erythematosus: distinguished by positive anti-dsDNA and malar rash
Myelodysplastic syndrome: distinguished by dysplastic features on bone marrow biopsy
Hypersplenism: distinguished by pancytopenia rather than isolated neutropenia
Sarcoidosis: distinguished by hilar adenopathy and non-caseating granulomas